Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
SAN DIEGO AND VANCOUVER, Aug. 5, 2013 /PRNewswire/ - Sophiris Bio Inc. (Sophiris, TSX: SHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced financial results and recent key operational highlights for the three and six months ended June 30, 2013.
Hey, check out all the research scientist jobs. Post your resume today!
